DHEA in Optimally Replaced Adrenal Insufficiency: Two Guidelines, One Patient
A single patient optimally replaced on every marker the team already tracks, whose remaining symptom sits at the exact point where two guidelines from the same professional society diverge.
Isabel N., a 37-year-old woman, returned six months ago from a year teaching English abroad, a decision she made partly because her Addison's disease, diagnosed at 29, had finally felt well-managed enough to risk being far from her regular endocrinologist. Her hydrocortisone and fludrocortisone doses have not changed in over a year, her day curve and electrolytes are both unremarkable, and by every marker the team already tracks, she is optimally replaced. What brought her back to clinic is something none of those markers capture: a persistent flatness in her energy and libido that predates her trip and never resolved, which she describes not as depression but as "missing a gear that used to be there." She is not on hormonal contraception, has no other medication that would independently blunt libido, and her thyroid panel — checked given her known autoimmune history — is normal. She read about DHEA replacement online and is asking directly whether it is worth trying, and says plainly that she would rather try something with an honest chance of helping than be told, again, that everything looks fine on paper.
The honest answer is that the Endocrine Society's own guidance does not fully agree with itself on this question. Its 2016 primary adrenal insufficiency guideline states DHEA replacement, 25 to 50 mg once daily, "may be considered" for exactly her presentation — persistent low energy or libido despite optimized glucocorticoid and mineralocorticoid replacement — citing Arlt and Callies' 1999 randomized trial, which found real improvement in mood and sexuality. Its separate 2014 Androgen Therapy in Women guideline, addressing the same drug in a broader population that includes adrenal insufficiency, instead recommends AGAINST its routine use, graded 1|⊕○○○ — a strong recommendation built on evidence its own authors call very low quality. A later trial, Lovas et al. 2003, found no benefit over nine months on the same subjective measures Arlt and Callies had improved. Both guidelines are real, current, and pointing in different directions from the same professional body.
Clinic visit, discussing DHEA replacement
She's optimally replaced on everything we already measure, which is exactly the population our own 2016 guideline had in mind when it said DHEA may be considered for persistent low energy or libido despite optimized glucocorticoid and mineralocorticoid dosing. Arlt and Callies' original trial showed real improvement in mood and sexuality on 50 mg daily. I think offering it is reasonable.
I'd want her to hear the rest of what our own society says before she decides. The 2014 Androgen Therapy in Women guideline recommends against routine DHEA use, graded on evidence its own authors call very low quality — and Lovas et al.'s later trial found no benefit on the same measures Arlt and Callies improved. That's not settled science pointing one direction with a footnote of caution; it's two guidelines from the same body genuinely disagreeing.
The visible side effects — hirsutism, acne — are the ones patients ask about, but the one that worries me is the one nobody can currently quantify: DHEA aromatizes to estrogen, and what that means for long-term cancer risk in a 37-year-old isn't a solved question, it's an open one neither guideline actually answers.
I don't think we have to pick a side of a guideline conflict tonight. Offer her a three-month trial at 25 mg, baseline DHEA-S and a validated well-being score today, repeat both at three months, and set the stop rule in advance: no meaningful improvement, or any new hirsutism or acne, and we discontinue. That turns an unresolved guideline disagreement into a real answer for her specifically, on a timeline short enough that the long-term-risk question stays honestly unresolved rather than quietly decided by default.
Agreed: a three-month bounded trial of DHEA 25 mg daily with baseline and follow-up DHEA-S and well-being scores, and a pre-set stop rule for no benefit or new androgenic side effects.
Not agreed: what happens if the trial shows a real, modest benefit. The endocrinologist would continue it indefinitely with routine monitoring; the women's health physician wants any continued use revisited against the unresolved cancer-risk question at a fixed future interval, not treated as settled once the three-month trial looks positive.